Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/selective-jak1-inhibitor-zemprocitinib-hits-efficacy-targets-2026a1000iy3?src=rss
Author :
Publish date : 2026-06-06 15:05:00
Copyright for syndicated content belongs to the linked Source.
